Expressão do recetor da calcitonina nos carcinomas medulares da tiroide

envie a um amigo share this

Expressão do recetor da calcitonina nos carcinomas medulares da tiroide

Terça, 24.10.2017

O carcinoma medular da tiroide (CMT) é um tumor raro, representando cerca de 5-10% de todos os carcinomas da tiroide, com uma taxa de sobrevida livre de doença aos 10 anos de 50-75%. Este carcinoma provém de um tipo particular de células tiroideias, denominadas células C, produtoras de calcitonina (CT). Os níveis séricos de CT são um marcador de diagnóstico muito sensível e especifico dos CMT, no entanto, o potencial papel do recetor da calcitonina (RCT) relativamente à agressividade tumoral e prognóstico, permanece desconhecido. Para tentar explorar o papel do RCT no CMT, o grupo Cancer Signaling and Metabolism do i3S/Ipatimup, avaliou a sua expressão numa série de CMT e procurou possíveis associações com características clinicopatológicas, moleculares e prognóstico. Os resultados deste estudo demonstraram que o RCT se encontra expresso na maioria dos CMT. Para além disso a sua expressão associou-se a um maior grau de diferenciação tumoral e a características clínicas e moleculares de melhor prognóstico. São necessários mais estudos para clarificar qual a função do RCT em células C normais e também tumorais.

 

Autores e Afiliações:

Virginia Cappagli1,2, Catarina Soares Potes3,4,5, Luciana Bueno Ferreira1,3,6, Catarina Tavares1,3,6, Catarina Eloy1,3, Rossella Elisei2, Manuel Sobrinho-Simões1,3,7,8, Peter J. Wookey9, Paula Soares1,3,6,8

1 Cancer Biology, Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal

2 Department of Clinical and Experimental Medicine - Endocrine Section, University of Pisa, Pisa, Italy

3 Cancer Signalling and Metabolism, Instituto de Investigac€a.o e Inovac€a.o em Sau.de - I3S, Porto, Portugal

4 Institute for Molecular and Cell Biology (IBMC), Porto, Portugal

5 Department of Experimental Biology, Faculty of Medicine, University of Porto, Porto, Portugal

6 Department of Pathology and Oncology, Medical Faculty, University of Porto and IPATIMUP, Porto, Portugal

7 Department of Medicine at Austin Health, University of Melbourne, Heidelbeg, Victoria, Australia

 

Abstract:

Background: Calcitonin expression is a well-established marker for medullary thyroid carcinoma (MTC); yet the role of calcitonin receptor (CTR), its seven-transmembrane G-protein coupled receptor, remains to be established in C-cells derived thyroid tumors. The aim of this work was to investigate CTR expression in MTC and to correlate such expression with clinicopathological features in order to evaluate its possible role as a prognostic indicator of disease aggressiveness and outcome. Methods: Calcitonin receptor expression was analyzed in a series of 75 MTCs by immunohistochemistry, and by qPCR mRNA quantification in specimens from four patients. Statistical tests were used to evaluate the correlation between CTR expression and the clinicopathological and molecular characteristics of patients and tumors. Results: Calcitonin receptor expression was detected in 62 out of 75 samples (82.7%), whereas 13 of the 75 samples (17.3%) were completely negative. CTR expression was significantly associated with expression of cytoplasmatic phosphatase and tensin homologue deleted on chromosome 10 and osteopontin, as well as with wild type RET/RAS genes and absence of tumor stroma, suggesting that CTR expression do not associate with clinicopathological signs of worse prognosis. Discussion: Calcitonin receptor expression appears to be associated in MTC with more differentiated status of the neoplastic cells.

 

Revista: PeerJ

 

Link: https://doi.org/10.7717/peerj.3778